Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models-Reference-Cited by-同舟云学术

Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models

Published:2015-11-23 Issue:11 Volume:10 Page:e0142612
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Daudigeos-Dubus Estelle,Le Dret Ludivine,Lanvers-Kaminsky Claudia,Bawa Olivia,Opolon Paule,Vievard Albane,Villa Irène,Pagès Mélanie,Bosq Jacques,Vassal Gilles,Zopf Dieter,Geoerger Birgit

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference60 articles.

1. Angiogenesis in health and disease;P Carmeliet;Nat Med,2003

2. High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies;M Taylor;Clin Cancer Res Off J Am Assoc Cancer Res,2009

3. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma;AS Chan;Am J Surg Pathol,1998

4. Angiogenesis of glioma: evaluation of ultrastructural characteristics of microvessels and tubular bodies (Weibel-Palade) in endothelial cells and immunohistochemical findings with VEGF and p53 protein;M Miyagami;Med Mol Morphol,2005

5. Vascular endothelial growth factor serum levels in children with newly diagnosed rhabdomyosarcoma;A Schiavetti;Pediatr Blood Cancer,2012

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gastrointestinal Stromal Tumors (GISTs) in Pediatric Patients: A Case Report and Literature Review;Children;2024-08-26

2. CHOP regulated by METTL14-m6A affects cell cycle arrest and regorafenib sensitivity in HCC cells;BMC Cancer;2024-04-25

3. Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG);Cancers;2024-02-29

4. Reirradiation with radiosurgery or stereotactic fractionated radiotherapy in association with regorafenib in recurrent glioblastoma;Strahlentherapie und Onkologie;2023-11-21

5. Decreased eukaryotic initiation factors expression upon temozolomide treatment—potential novel implications for eIFs in glioma therapy;Journal of Neuro-Oncology;2023-10